NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PTCT

PTC Therapeutics Inc

Jul 03 • 04:00PM ET

49.07

Dollar change -0.08
Percentage change -0.16	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: VTI IWM VB XBI VXF VBK CALF IWO IBB VTWO

Scroll to Statements

Index	RUT	P/E	7.54	EPS (ttm)	6.51	Insider Own	2.67%	Shs Outstand	79.23M	Perf Week	-0.97%
Market Cap	3.89B	Forward P/E	-	EPS next Y	-2.43	Insider Trans	-6.91%	Shs Float	77.14M	Perf Month	-3.20%
Enterprise Value	2.25B	PEG	-	EPS next Q	-1.06	Inst Own	98.46%	Short Float	6.58%	Perf Quarter	1.45%
Income	594.84M	P/S	2.19	EPS this Y	258.45%	Inst Trans	1.78%	Short Ratio	4.04	Perf Half Y	7.21%
Sales	1.77B	P/B	-	EPS next Y	-132.47%	ROA	26.76%	Short Interest	5.07M	Perf YTD	8.71%
Book/sh	-2.34	P/C	1.92	EPS next 5Y	-	ROE	-	52W High	58.38 -15.95%	Perf Year	57.43%
Cash/sh	25.58	P/FCF	5.61	EPS past 3/5Y	14.01% -2.04%	ROIC	317.51%	52W Low	29.01 69.12%	Perf 3Y	22.86%
Dividend Est.	-	EV/EBITDA	2.51	Sales past 3/5Y	14.42% 21.32%	Gross Margin	96.13%	Volatility	2.81% 2.96%	Perf 5Y	-6.84%
Dividend TTM	-	EV/Sales	1.27	EPS Y/Y TTM	198.37%	Oper. Margin	48.98%	ATR (14)	1.67	Perf 10Y	-4.68%
Dividend Ex-Date	-	Quick Ratio	3.85	Sales Y/Y TTM	91.12%	Profit Margin	33.55%	RSI (14)	48.20	Recom	1.88
Dividend Gr. 3/5Y	- -	Current Ratio	3.89	EPS Q/Q	939.01%	SMA20	-2.53%	Beta	0.54	Target Price	62.81
Payout	-	Debt/Eq	-	Sales Q/Q	459.73%	SMA50	1.62%	Rel Volume	0.24	Prev Close	49.15
Employees	939	LT Debt/Eq	-	Earnings	May 06 AMC	SMA200	6.41%	Avg Volume	1.25M	Price	49.07
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	1096.23% 592.11%	Trades		Volume	307,079	Change	-0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35

Show Previous Ratings

Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	Loading…
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Loading…
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Loading…
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
Dec-04-24 07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily) +18.66%
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)
12:40PM	PTC Therapeutics Stock Soars on Novartis Licensing Agreement (Investopedia)
11:29AM	Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% (GuruFocus.com)
07:00AM	PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program (PR Newswire)
05:56AM	Novartis wagers billions of dollars on PTC Huntingtons drug (BioPharma Dive)
Nov-28-24 07:11AM	PTC Therapeutics to sell Priority Review Voucher for $150M (TipRanks)
Nov-27-24 10:12AM	PTC Therapeutics ALS drug fails to meet endpoints as trials shut down (Clinical Trials Arena)
07:51AM	PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs (Benzinga)
07:00AM	PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million (PR Newswire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 04:30PM	PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients (PR Newswire) +7.02%
Nov-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-14-24 01:46PM	FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain (Benzinga)
10:00AM	FDA grants accelerated approval for PTCs AADC deficiency gene therapy (Pharmaceutical Technology)
06:28AM	PTC wins US approval of gene therapy for fatal enzyme disorder (BioPharma Dive)
Nov-13-24 06:02PM	PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy (PR Newswire)
Nov-08-24 10:05AM	PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 06:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-06-24 09:15AM	Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks) +5.65%
07:11AM	PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Nov-01-24 06:06AM	Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug (BioPharma Dive)
Oct-30-24 07:00AM	PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission (PR Newswire)
Oct-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-24-24 07:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results (PR Newswire)
Oct-18-24 03:01PM	State Street Corp's Strategic Acquisition in PTC Therapeutics Inc (GuruFocus.com) +5.65%
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
06:30AM	CHMP Maintains Negative Opinion on Translarna Reexamination (PR Newswire)
Oct-17-24 10:01AM	Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-14-24 04:30PM	PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results (PR Newswire)
Oct-09-24 05:54PM	PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
03:07PM	PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? (Zacks)
Oct-08-24 08:00AM	PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program (PR Newswire) +16.52%
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
Oct-01-24 09:00AM	PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients (PR Newswire)
05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-26-24 08:00AM	FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program (PR Newswire)
Sep-12-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-28-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 03:33PM	PTC Therapeutics Stock Earns RS Rating Upgrade To 83 (Investor's Business Daily)
Aug-08-24 05:15PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:09PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 09:15AM	Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boulding Mark Elliott	EXEC. VP AND CLO	May 15 '25	Option Exercise	25.69	1,929	49,556	105,830	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 16 '25	Option Exercise	25.69	883	22,684	104,784	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 15 '25	Sale	46.18	1,929	89,081	103,901	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 16 '25	Sale	46.02	883	40,636	103,901	May 19 05:20 PM
Boulding Mark Elliott	Officer	May 16 '25	Proposed Sale	46.02	883	40,640		May 16 04:25 PM
Boulding Mark Elliott	Officer	May 15 '25	Proposed Sale	46.18	1,929	89,076		May 15 04:23 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 22 '25	Sale	48.74	2,804	136,656	273,234	Apr 24 05:20 PM
Klein Matthew B.	Officer	Apr 22 '25	Proposed Sale	48.74	2,804	136,656		Apr 22 03:14 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Apr 02 '25	Sale	46.95	897	42,114	75,997	Apr 04 05:20 PM
Golden Lee Scott	Officer	Apr 02 '25	Proposed Sale	46.95	897	42,117		Apr 02 03:24 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 17 '25	Sale	56.80	6,762	384,067	72,640	Mar 18 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 14 '25	Sale	55.19	4,458	246,037	79,402	Mar 18 05:20 PM
Okey Stephanie	Director	Mar 13 '25	Sale	54.00	5,000	270,000	8,867	Mar 17 05:20 PM
Pauwels Eric	Officer	Mar 17 '25	Proposed Sale	56.80	6,762	384,064		Mar 17 04:48 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Option Exercise	33.02	15,521	512,503	117,027	Mar 14 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Sale	53.30	15,521	827,233	103,901	Mar 14 05:20 PM
Pauwels Eric	Officer	Mar 14 '25	Proposed Sale	55.19	4,458	246,024		Mar 14 04:24 PM
Okey Stephanie	Director	Mar 13 '25	Proposed Sale	54.00	5,000	270,000		Mar 13 10:23 AM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Option Exercise	31.81	68,039	2,164,193	149,293	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Option Exercise	33.02	7,381	243,721	109,563	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Sale	53.09	68,039	3,611,982	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Sale	53.02	7,381	391,323	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	Officer	Mar 12 '25	Proposed Sale	53.30	15,521	827,199		Mar 12 04:33 PM
Boulding Mark Elliott	Officer	Mar 11 '25	Proposed Sale	53.02	7,381	391,321		Mar 11 04:21 PM
Boulding Mark Elliott	Officer	Mar 10 '25	Proposed Sale	53.09	68,039	3,612,075		Mar 10 04:28 PM
Jacobson Allan Steven	Director	Mar 04 '25	Sale	51.52	1,230	63,370	19,118	Mar 06 05:20 PM
Jacobson Allan Steven	Director	Mar 04 '25	Proposed Sale	51.52	1,230	63,365		Mar 04 12:35 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 19 '25	Sale	50.10	879	44,034	63,442	Feb 21 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 20 '25	Sale	50.12	878	44,009	62,564	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 19 '25	Sale	50.10	1,168	58,512	75,603	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 20 '25	Sale	50.12	1,167	58,495	74,436	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	1,567	78,544	83,860	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	1,378	69,032	85,427	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	3,895	195,233	276,038	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	3,897	195,224	279,933	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 20 '25	Sale	50.12	962	48,219	76,894	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 19 '25	Sale	50.10	795	39,826	77,856	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 20 '25	Sale	50.12	1,614	80,900	103,901	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 19 '25	Sale	50.10	1,333	66,778	105,515	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	1,578	79,096	100,353	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	1,300	65,125	101,931	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	34	1,704	5,907	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	34	1,703	5,941	Feb 21 05:20 PM
Almstead Neil Gregory	Officer	Feb 20 '25	Proposed Sale	50.12	1,578	79,096		Feb 20 04:47 PM
Almstead Neil Gregory	Member of immediate family of	Feb 20 '25	Proposed Sale	50.12	34	1,704		Feb 20 04:33 PM
Boulding Mark Elliott	Officer	Feb 20 '25	Proposed Sale	50.12	1,614	80,900		Feb 20 04:32 PM
Utter Christine Marie	Officer	Feb 20 '25	Proposed Sale	50.12	878	44,009		Feb 20 04:21 PM
Klein Matthew B.	Officer	Feb 20 '25	Proposed Sale	50.12	3,895	195,233		Feb 20 04:20 PM
Golden Lee Scott	Officer	Feb 20 '25	Proposed Sale	50.12	962	48,219		Feb 20 04:18 PM
Gravier Pierre	Officer	Feb 20 '25	Proposed Sale	50.12	1,167	58,495		Feb 20 04:17 PM
Pauwels Eric	Officer	Feb 20 '25	Proposed Sale	50.12	1,567	78,544		Feb 20 04:10 PM
Almstead Neil Gregory	Member of immediate family of	Feb 19 '25	Proposed Sale	50.10	34	1,703		Feb 19 04:36 PM
Almstead Neil Gregory	Officer	Feb 19 '25	Proposed Sale	50.10	1,300	65,125		Feb 19 04:34 PM
Utter Christine Marie	Officer	Feb 19 '25	Proposed Sale	50.10	879	44,035		Feb 19 04:27 PM
Gravier Pierre	Officer	Feb 19 '25	Proposed Sale	50.10	1,168	58,513		Feb 19 04:25 PM
Boulding Mark Elliott	Officer	Feb 19 '25	Proposed Sale	50.10	1,333	66,778		Feb 19 04:18 PM
Klein Matthew B.	Officer	Feb 19 '25	Proposed Sale	50.10	3,897	195,226		Feb 19 04:18 PM
Golden Lee Scott	Officer	Feb 19 '25	Proposed Sale	50.10	795	39,827		Feb 19 04:13 PM
Pauwels Eric	Officer	Feb 19 '25	Proposed Sale	50.10	1,378	69,033		Feb 19 04:11 PM
Bell William F. Jr.	Former Director	Feb 03 '25	Proposed Sale	50.00	10,556	527,800		Feb 03 02:14 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '25	Sale	44.50	1,662	73,959	64,321	Jan 10 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '25	Sale	45.34	1,291	58,534	65,983	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,136	95,052	86,805	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	1,599	72,499	88,941	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,402	106,889	283,830	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	2,142	97,118	286,232	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '25	Sale	44.50	1,198	53,311	78,651	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '25	Sale	45.34	810	36,725	79,849	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '25	Sale	44.50	1,998	88,911	106,848	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '25	Sale	45.34	1,543	69,960	108,846	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	1,552	69,064	103,231	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	1,265	57,355	104,783	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	107	4,762	5,975	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	55	2,494	6,082	Jan 10 05:20 PM
Bell William F. Jr.	Former Director	Jan 10 '25	Proposed Sale	44.57	6,666	297,104		Jan 10 04:44 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '25	Proposed Sale	44.50	107	4,761		Jan 08 05:29 PM
Golden Lee Scott	Officer	Jan 08 '25	Proposed Sale	44.50	1,198	53,311		Jan 08 05:19 PM
Almstead Neil Gregory	Officer	Jan 08 '25	Proposed Sale	44.50	1,552	69,064		Jan 08 05:18 PM
Pauwels Eric	Officer	Jan 08 '25	Proposed Sale	44.50	2,136	95,052		Jan 08 05:06 PM
Klein Matthew B.	Officer	Jan 08 '25	Proposed Sale	44.50	2,402	106,889		Jan 08 05:01 PM
Utter Christine Marie	Officer	Jan 08 '25	Proposed Sale	44.50	1,662	73,959		Jan 08 04:51 PM
Boulding Mark Elliott	Officer	Jan 08 '25	Proposed Sale	44.50	1,998	88,911		Jan 08 04:46 PM
Golden Lee Scott	Officer	Jan 07 '25	Proposed Sale	45.34	810	36,723		Jan 07 04:42 PM
Boulding Mark Elliott	Officer	Jan 07 '25	Proposed Sale	45.34	1,543	69,956		Jan 07 04:38 PM
Klein Matthew B.	Officer	Jan 07 '25	Proposed Sale	45.34	2,142	97,113		Jan 07 04:31 PM
Pauwels Eric	Officer	Jan 07 '25	Proposed Sale	45.34	1,599	72,495		Jan 07 04:31 PM
Almstead Neil Gregory	Officer	Jan 07 '25	Proposed Sale	45.34	1,265	57,352		Jan 07 04:24 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '25	Proposed Sale	45.34	55	2,494		Jan 07 04:24 PM
Utter Christine Marie	Officer	Jan 07 '25	Proposed Sale	45.34	1,291	58,531		Jan 07 04:13 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 31 '24	Sale	45.16	8,279	373,880	217,528	Jan 03 05:21 PM
Klein Matthew B.	Director	Dec 31 '24	Proposed Sale	45.16	8,279	373,876		Dec 31 03:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	69,550	3,547,050	153,158	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	2,060	105,060	6,636	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	52.06	69,550	3,620,895	86,202	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	51.97	2,060	107,063	4,576	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Option Exercise	40.93	24,000	982,320	26,500	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Sale	51.50	24,000	1,235,897	14,500	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Option Exercise	51.00	17,800	907,800	67,123	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Sale	51.77	17,800	921,585	52,428	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 02 '24	Option Exercise	51.00	85,600	4,365,600	176,029	Dec 04 05:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience